About: Coronavirus Disease 2019 in Children: Characteristics, Antimicrobial Treatment, and Outcomes

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Coronavirus Disease 2019 in Children: Characteristics, Antimicrobial Treatment, and Outcomes Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Coronavirus Disease 2019 in Children: Characteristics, Antimicrobial Treatment, and Outcomes
Creator	Wang, Yang Xu, Hua Peng, Hui Peng, Jing Jiang, Kong, Hong Wang, J Gao, Ping Liu, Maochang Xu, Qiong Coronavirus, Xu Peng, Liu
Source	Elsevier; Medline; PMC
abstract	Abstract Background At present, coronavirus disease 2019 (COVID-19) has spread in many countries. We conducted this study to help paediatricians To help pediatricians understand the conditions of COVID-19 in children, we conducted this study. Methods We retrospectively summarized the characteristics, treatment and outcomes of pediatric cases in Wuhan children's hospital which was the only designated hospital for children with COVID-19 in Hubei Province. A Cox proportional hazards regression analysis was used to evaluate factors associated with clinical outcomes. Results As of February 29, 75 children had been discharged, of which only one was has severe pneumonia and one was critical cases. Children younger than 2 years were more susceptible to COVID-19. All patients have received interferon-α nebulization, and eight cases including the severe and critical cases were co-administrated ribavirin. Five patients with mild pneumonia were given arbidol. Twenty-three patients were given traditional Chinese medicine (TCM). The average length of stay (LOS) and the time of SARS-CoV-2 clearance were 10.57 and 6.39 days, respectively. None of the factors was associated with LOS or time of SARS-CoV-2 clearance. Conclusions The severity of COVID-19 in pediatric cases were milder than adults. The efficacy of the antiviral therapy in children with COVID-19 remains to be evaluated.
has issue date	2020-05-07(xsd:dateTime)
bibo:doi	10.1016/j.jcv.2020.104425
bibo:pmid	32446167
has license	els-covid
sha1sum (hex)	e88a27077600c9c17381f66f91cff4b3a4b2a353
schema:url	https://doi.org/10.1016/j.jcv.2020.104425
resource representing a document's title	Coronavirus Disease 2019 in Children: Characteristics, Antimicrobial Treatment, and Outcomes
has PubMed Central identifier	PMC7204737
has PubMed identifier	32446167
schema:publication	J Clin Virol
resource representing a document's body	covid:e88a27077600c9c17381f66f91cff4b3a4b2a353#body_text
is schema:about of	named entity 'Highlights' named entity 'Outcomes' named entity 'Antimicrobial' covid:arg/e88a27077600c9c17381f66f91cff4b3a4b2a353 named entity 'Running' named entity 'COVID-19' named entity 'Word count' named entity 'SARS' named entity 'sputum' named entity 'pediatric patients' named entity 'nucleic acid' named entity 'cure rate' named entity 'TCM' named entity 'COVID' named entity 'Center for Disease Control and Prevention' named entity 'SARS-CoV-2' named entity 'clinical characteristics' named entity 'interferon' named entity 'pediatric' named entity 'Interferon-α' named entity 'clinical outcomes' named entity 'COVID' named entity 'Russia' named entity 'clinical symptoms' named entity 'lopinavir' named entity 'China' named entity 'dry cough' named entity 'clinical characteristics' named entity 'upper respiratory tract infection' named entity 'Middle East respiratory syndrome' named entity 'ground-glass opacity' named entity 'MERS' named entity 'COVID-19' named entity 'ribavirin' named entity 'fatigue' named entity 'clinical outcomes' named entity 'epidemiological study' named entity 'coronavirus disease 2019' named entity 'RT-PCR' named entity 'China' named entity 'pediatric patients' named entity 'oropharyngeal' named entity 'Young children' named entity 'COVID' named entity 'SARS-CoV-2' named entity 'chest CT' named entity 'sample size' named entity 'fever' named entity 'arbidol' named entity 'COVID' named entity 'creatine kinase' named entity 'Cox model' named entity 'COVID-19' named entity 'February 19' named entity 'pediatric patients' named entity 'COVID-19' named entity 'antiviral agent' named entity 'nebulization' named entity 'February 29' named entity 'pediatric' named entity 'treatment of children' named entity 'arbidol' named entity 'pneumonia' named entity 'western medicine' named entity 'severe acute respiratory syndrome coronavirus 2' named entity 'COVID' named entity 'clinical symptom' named entity 'antiviral drugs' named entity 'clinical outcomes' named entity 'SARS-CoV-2'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software